# Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review

Review · Motamedi H, Ari MM, Alvandi A, Abiri R

- Archive id: doi:10.3389/fmicb.2024.1393646
- Published: 2024-06-13
- Venue: Frontiers in microbiology
- DOI: https://doi.org/10.3389/fmicb.2024.1393646
- PMID: 38939184
- PMCID: PMC11208694
- Citations: 27
- Source URL: https://doi.org/10.3389/fmicb.2024.1393646
- PDF: https://europepmc.org/articles/PMC11208694/pdf
- Provenance: europepmc

## Abstract

While significant progress has been made in understanding and applying gene silencing mechanisms and the treatment of human diseases, there have been still several obstacles in therapeutic use. For the first time, ONPATTRO, as the first small interfering RNA (siRNA) based drug was invented in 2018 for treatment of hTTR with polyneuropathy. Additionally, four other siRNA based drugs naming Givosiran, Inclisiran, Lumasiran, and Vutrisiran have been approved by the US Food and Drug Administration and the European Medicines Agency for clinical use by hitherto. In this review, we have discussed the key and promising advances in the development of siRNA-based drugs in preclinical and clinical stages, the impact of these molecules in bacterial and viral infection diseases, delivery system issues, the impact of administration methods, limitations of siRNA application and how to overcome them and a glimpse into future developments.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.